Trials / Recruiting
RecruitingNCT05733013
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Surveillance Visit | Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit. |
Timeline
- Start date
- 2023-02-07
- Primary completion
- 2028-02-07
- Completion
- 2028-02-07
- First posted
- 2023-02-17
- Last updated
- 2025-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05733013. Inclusion in this directory is not an endorsement.